Literature DB >> 810549

Correlation of neoplasms with incidence and localization of skeletal metastases: An analysis of 1,355 diphosphonate bone scans.

A J Tofe, M D Francis, W J Harvey.   

Abstract

A total of 1,355 patients from clinical trails with the 99mTc-labeled bone agent, Osteoscan (99mTc-Sn -EHDP), has shown a higher incidence of skeletal abnormalities than previously reported. Overall in this study, 60% of bone scans were abnormal in patients with nonosseous neoplasms. Carcinoma of breast, lung, and prostate yielded 67%, 64%, and 62% skeletal involvement, respectively. Over 50% of all the skeletal abnormalities for the neoplastic indications were detected in the thorax and vertebra while the skull, pelvis, and extremities accounted for 22%, 38%, and 34%, respectively.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 810549

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  27 in total

1.  Orthopedics-epitomes of progress: nuclear medicine and bone cancer.

Authors:  N Telfer
Journal:  West J Med       Date:  1980-11

2.  Lung cancer underlying paravertebral abscess with intramedullary spinal cord metastases.

Authors:  Laura Iliescu; Letitia Toma
Journal:  BMJ Case Rep       Date:  2013-09-13

Review 3.  The use of diffusion weighted imaging to evaluate pathology outside the brain parenchyma in neuroimaging studies.

Authors:  Philip Benjamin; Faraan Khan; Andrew D MacKinnon
Journal:  Br J Radiol       Date:  2017-02-14       Impact factor: 3.039

Review 4.  Strategies for management of prostate cancer-related bone pain.

Authors:  R C Pelger; V Soerdjbalie-Maikoe; N A Hamdy
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

5.  Quantitative assessment of 99mTc-MDP scans in investigation of diffuse alterations in bone.

Authors:  J P Pfeifer; U Büll; H Pfeifer
Journal:  Eur J Nucl Med       Date:  1979-12

6.  Comparison of distribution characteristics of metastatic bone lesions between breast and prostate carcinomas.

Authors:  Chang-Yin Wang; Guang-Yao Wu; Mei-Juan Shen; Kun-Wei Cui; Ying Shen
Journal:  Oncol Lett       Date:  2012-10-30       Impact factor: 2.967

Review 7.  Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.

Authors:  Laura Evangelista; Francesco Bertoldo; Francesco Boccardo; Giario Conti; Ilario Menchi; Francesco Mungai; Umberto Ricardi; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-09       Impact factor: 9.236

8.  Fractionated external beam radiotherapy of skull base metastases with cranial nerve involvement.

Authors:  L H Dröge; T Hinsche; M Canis; B Alt-Epping; C F Hess; H A Wolff
Journal:  Strahlenther Onkol       Date:  2013-12-22       Impact factor: 3.621

9.  Diphosphonates in the evaluation of metabolic bone disease.

Authors:  I Fogelman; M L Smith
Journal:  Clin Rheumatol       Date:  1982-03       Impact factor: 2.980

10.  Update in palliative management of hormone refractory cancer of prostate.

Authors:  Pratipal Singh; Aneesh Srivastava
Journal:  Indian J Urol       Date:  2007-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.